Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.54 |
| ▸ | ITGAV | P06756 | 7/20 | 0.54 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.52 |
| ▸ | MC4R | P32245 | 9/20 | 0.52 |
| ▸ | MC5R | P33032 | 9/20 | 0.52 |
| ▸ | MC3R | P41968 | 9/20 | 0.52 |
| ▸ | MC1R | Q01726 | 9/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19605458 | 0.93 | ITGB3 (0.58) | ITGB3ITGAVITGB5ITGA2BMC4R | |
| SCHEMBL20888358 | 0.93 | ITGB3 (0.58) | ITGB3ITGAVITGB5ITGA2BMC4R | |
| SCHEMBL21766911 | 0.93 | ITGB3 (0.58) | ITGB3ITGAVITGB5ITGA2BMC4R | |
| SCHEMBL22872704 | 0.92 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BMC4R | |
| SCHEMBL23018575 | 0.90 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGA2BMC4R | |
| SCHEMBL14885797 | 0.90 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGA2BMC4R | |
| SCHEMBL12496488 | 0.90 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGA2BMC4R | |
| SCHEMBL13881412 | 0.89 | ITGB3 (0.58) | ITGB3ITGAVITGB5ITGA2BMC4R | |
| SCHEMBL21475019 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGA2BMC4R | |
| SCHEMBL14885799 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGA2BMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10753941-B2 | Biocompatible nanoparticles with aggregation induced emission characteristics as fluorescent bioprobes and methods of using the same for in vitro and in vivo imaging | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2020-08-25 | — | — | US | disclosed |
| US-20140328764-A1 | Biocompatible Nanoparticles with Aggregation Induced Emission Characteristics as Fluorescent Bioprobes and Methods of Using the Same for In Vitro and In Vivo Imaging | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-06 | — | — | US | disclosed |
| US-20140328764-A1 | Biocompatible Nanoparticles with Aggregation Induced Emission Characteristics as Fluorescent Bioprobes and Methods of Using the Same for In Vitro and In Vivo Imaging | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-06 | — | — | US | disclosed |
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008134761-A2 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | CD44, CD47, EPCAM | ITGB3 24/4885ITGAV 70/4885ITGB5 26/4885 |
| US-10753941-B2 | Biocompatible nanoparticles with aggregation induced emission characteristics as fluorescent bioprobes and methods of using the same for in vitro and in vivo imaging | LGALS3, LGALS1, CD63 | ITGB3 609/4885ITGAV 1436/4885ITGB5 2902/4885 |
| US-20140328764-A1 | Biocompatible Nanoparticles with Aggregation Induced Emission Characteristics as Fluorescent Bioprobes and Methods of Using the Same for In Vitro and In Vivo Imaging | LGALS3, LGALS1, CD63 | ITGB3 609/4885ITGAV 1436/4885ITGB5 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.